Constellation Pharmaceuticals (CNST) Posts Earnings Results, Misses Expectations By $0.03 EPS

Constellation Pharmaceuticals (NASDAQ:CNST) released its quarterly earnings results on Thursday. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.03), Fidelity Earnings reports.

CNST stock opened at $10.00 on Friday. Constellation Pharmaceuticals has a twelve month low of $4.01 and a twelve month high of $12.45.

An institutional investor recently raised its position in Constellation Pharmaceuticals stock. Geode Capital Management LLC boosted its holdings in Constellation Pharmaceuticals Inc (NASDAQ:CNST) by 16.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,735 shares of the company’s stock after purchasing an additional 1,987 shares during the quarter. Geode Capital Management LLC owned approximately 0.05% of Constellation Pharmaceuticals worth $55,000 at the end of the most recent quarter. 60.05% of the stock is owned by institutional investors and hedge funds.

CNST has been the subject of a number of recent analyst reports. Robert W. Baird initiated coverage on shares of Constellation Pharmaceuticals in a research report on Monday, January 28th. They set an “outperform” rating and a $17.00 price target for the company. HC Wainwright initiated coverage on shares of Constellation Pharmaceuticals in a research report on Thursday, December 20th. They set a “buy” rating and a $18.00 price target for the company. ValuEngine downgraded shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Finally, Zacks Investment Research raised shares of Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research report on Wednesday, January 9th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Constellation Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $17.25.

TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at

Constellation Pharmaceuticals Company Profile

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

See Also: Why do earnings reports matter?

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with's FREE daily email newsletter.